Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer

Vanderbilt University Medical Center

Status: Withdrawn

Conditions: Liver Cancer

Treatments: Genetic: comparative genomic hybridization; Genetic: molecular genetic technique; Genetic: mutation analysis; Other: immunohistochemistry staining method; Genetic: proteomic profiling; Other: mass spectrometry; Other: medical chart review; Other: laboratory biomarker analysis; Genetic: polymerase chain reaction

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00899002

VICC GI 0611

VU-VICC-060479

VU-VICC-GI-0611

Details and patient eligibility

About

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at biomarkers in stored tumor samples from younger patients with liver cancer.

Full description

OBJECTIVES:

• To characterize, at a molecular level, archived samples of tissue from young patients with fibrolamellar carcinoma and hepatocellular carcinoma in non-cirrhotic livers matched for age and sex.
• To perform genomic analysis on these tissue samples using array comparative genomic hybridization.
• To perform targeted gene mutation analysis on these samples by PCR.
• To perform proteomic profiling on fixed tissues in these samples by various proteomic methods, including IHC and mass spectrometry.
• To look for association between molecular aberrations and clinicopathologic features in these samples.

OUTLINE: Archived tissue samples are collected from the pathology department at Vanderbilt University Medical Center and from the Mayo Clinic in Rochester, Minnesota. Tissue samples are analyzed by genomic analysis using array comparative genomic hybridization, target gene mutation analysis by PCR, and proteomic profiling on fixed tissues using various proteomic methods, including IHC and mass spectrometry. Samples are also examined for association between molecular aberrations and clinicopathologic features found in each disease.

Clinical patient data (i.e., age, sex, race, date of diagnosis, risk factors, histology, surgical staging, follow-ups, date of death, and adjuvant therapy) are also collected.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

DISEASE CHARACTERISTICS:

• Diagnosis of fibrolamellar carcinoma or hepatocellular carcinoma in a non-cirrhotic liver
• Archived tumor specimens available for analysis from Vanderbilt University or Mayo Clinic

Exclusion criteria

• Not specified

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified